Patent No. EP3781132 (titled "Apixaban Formulations") was filed by Bristol Myers Squibb on Apr 15, 2019. The application was issued on Mar 20, 2024.
A novel formulation for oral administration of apixaban that enables controlled release of the anticoagulant in food and beverages. The formulation comprises a treated core comprising a core substrate and apixaban and a carrier on the core substrate, wherein the apixaban and carrier are in a layer formed on a surface of the core substrate. The treated core is formed through a spray-layered dispersion process with apixaban in a solvent below its solubility limit. The formulation is suitable for administration through capsules, sticks, or other delivery systems that can be dispensed or dissolved in food or beverages.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.